This is therefore a contrasting of the institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation in Applied Genetic Technologies Corporation (NASDAQ:AGTC) and Dare Bioscience Inc. (NASDAQ:DARE). The two are both Biotechnology companies that compete with one another.
Earnings & Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Applied Genetic Technologies Corporation | 3 | 0.00 | 11.34M | 0.10 | 39.39 |
Dare Bioscience Inc. | 1 | 0.00 | 14.35M | -1.06 | 0.00 |
Table 1 shows gross revenue, earnings per share and valuation of the two companies.
Profitability
Table 2 shows us Applied Genetic Technologies Corporation and Dare Bioscience Inc.’s net margins, return on assets and return on equity.
Net Margins | Return on Equity | Return on Assets | |
Applied Genetic Technologies Corporation | 385,635,584.57% | 2.2% | 1.7% |
Dare Bioscience Inc. | 1,754,493,214.33% | -150.1% | -130.6% |
Risk & Volatility
Applied Genetic Technologies Corporation has a beta of 2.51 and its 151.00% more volatile than Standard and Poor’s 500. Dare Bioscience Inc.’s 96.00% more volatile than Standard and Poor’s 500 volatility due to the company’s 1.96 beta.
Liquidity
10.9 and 10.9 are the respective Current Ratio and a Quick Ratio of Applied Genetic Technologies Corporation. Its rival Dare Bioscience Inc.’s Current and Quick Ratios are 4.2 and 4.2 respectively. Applied Genetic Technologies Corporation has a better chance of clearing its pay short and long-term debts than Dare Bioscience Inc.
Analyst Ratings
The following table shown below contains the ratings and recommendations for Applied Genetic Technologies Corporation and Dare Bioscience Inc.
Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
Applied Genetic Technologies Corporation | 0 | 0 | 3 | 3.00 |
Dare Bioscience Inc. | 0 | 0 | 0 | 0.00 |
Applied Genetic Technologies Corporation’s upside potential currently stands at 214.57% and an $9.5 average target price.
Institutional & Insider Ownership
The shares of both Applied Genetic Technologies Corporation and Dare Bioscience Inc. are owned by institutional investors at 55.1% and 8.2% respectively. 0.5% are Applied Genetic Technologies Corporation’s share owned by insiders. Comparatively, Dare Bioscience Inc. has 0.8% of it’s share owned by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
Applied Genetic Technologies Corporation | -3.98% | 4.32% | -8.31% | 30.41% | -5.28% | 55.02% |
Dare Bioscience Inc. | 2.17% | -6.1% | -25.07% | -3.97% | -31.58% | 7.85% |
For the past year Applied Genetic Technologies Corporation has stronger performance than Dare Bioscience Inc.
Summary
On 8 of the 11 factors Applied Genetic Technologies Corporation beats Dare Bioscience Inc.
Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.